Clinical Trial Update: A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating tremelimumab and IV durvalumab with Poly-ICLC in biopsy-accessible cancers; completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Cutaneous T-cell Lymphoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Merkel Cell Carcinoma
• Prostate Cancer
• Renal Cancer
• Sarcoma
• Solid Tumor
• Testicular Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Poly-ICLC (poly-ICLC)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Head and Neck Squamous Cell Carcinoma, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-02